GB201206761D0 - Anti-atherogenic peptides - Google Patents

Anti-atherogenic peptides

Info

Publication number
GB201206761D0
GB201206761D0 GB201206761A GB201206761A GB201206761D0 GB 201206761 D0 GB201206761 D0 GB 201206761D0 GB 201206761 A GB201206761 A GB 201206761A GB 201206761 A GB201206761 A GB 201206761A GB 201206761 D0 GB201206761 D0 GB 201206761D0
Authority
GB
United Kingdom
Prior art keywords
peptides
atherogenic
relates
inflammatory
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201206761A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thrombosis Research Institute
Original Assignee
Thrombosis Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombosis Research Institute filed Critical Thrombosis Research Institute
Priority to GB201206761A priority Critical patent/GB201206761D0/en
Publication of GB201206761D0 publication Critical patent/GB201206761D0/en
Priority to PCT/GB2013/050972 priority patent/WO2013156771A1/en
Ceased legal-status Critical Current

Links

Abstract

Theinvention relates to novel nucleic acids and peptides having anti atherogenic and/or anti-inflammatory activity. In particular, the invention relates to a combination therapy of two or more peptides for treating autoimmune disease and/or inflammatory disease. It also relates to methods of making and using such peptides, intermediates useful in the manufacture of such peptides, formulations comprising such peptides, and to other subject matter.
GB201206761A 2012-04-17 2012-04-17 Anti-atherogenic peptides Ceased GB201206761D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201206761A GB201206761D0 (en) 2012-04-17 2012-04-17 Anti-atherogenic peptides
PCT/GB2013/050972 WO2013156771A1 (en) 2012-04-17 2013-04-16 Anti-atherogenic peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201206761A GB201206761D0 (en) 2012-04-17 2012-04-17 Anti-atherogenic peptides

Publications (1)

Publication Number Publication Date
GB201206761D0 true GB201206761D0 (en) 2012-05-30

Family

ID=46209210

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201206761A Ceased GB201206761D0 (en) 2012-04-17 2012-04-17 Anti-atherogenic peptides

Country Status (2)

Country Link
GB (1) GB201206761D0 (en)
WO (1) WO2013156771A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2539743A (en) * 2015-01-27 2016-12-28 Thrombosis Res Inst Multi-eptopic construct
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480974A (en) * 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
CA2758213C (en) * 2008-04-10 2017-08-15 Thrombosis Research Institute Anti-atheroma vaccine

Also Published As

Publication number Publication date
WO2013156771A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2018016389A (en) Compositions and methods for delivering messenger rna.
MX2017014908A (en) Trispecific binding proteins and methods of use.
EA201591281A1 (en) RIBONUCLEIC ACIDS WITH 4'-THIOMODIFIED NUCLEOTIDES AND RELATED METHODS
MY160608A (en) APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
EA201791693A1 (en) HETERODIMERNY IMMUNOHLOBULINS
WO2014096425A3 (en) Prodrugs of monomethyl fumarate (mmf)
EA201590910A1 (en) PROTEINS BASED ON A STRUCTURAL FIBRONECTIN DOMAIN, CONNECTING PCSK9
JO3462B1 (en) Human Antibodies to GFR?3 and methods of use thereof
WO2014151456A3 (en) Treatment of inflammatory diseases
CY1116304T1 (en) USE OF BIOTINE FOR THERAPEUTIC TREATMENT
NZ616989A (en) Therapeutic nuclease compositions and methods
EP2614085A4 (en) Anti-il-1 beta antibodies and methods of use
BR112013009083A8 (en) human oncostatin m antibodies and methods of use
MX2013011421A (en) Pyrazolo pyrimidine derivatives.
MX365403B (en) Peptides and methods of using same.
MX350445B (en) Complement factor b analogs and their uses.
UA105073C2 (en) Anti-fractalkine antibody, composition and method for treating inflammatory disorders
IN2014DN03213A (en)
MX357656B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases.
MX2015016120A (en) Binding molecules that bind human complement factor c2 and uses thereof.
WO2013023059A3 (en) Methods and compositions for the treatment of autoimmune and inflammatory diseases
IN2014CN00510A (en)
MX361773B (en) Tlr3 binding agents.
EP3377622A4 (en) Targeted delivery of therapeutic proteins bioencapsulated in plant cells to cell types of interest for the treatment of disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)